We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+0.59%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$266M
AUM Growth
+$34.2M
Cap. Flow
+$31.7M
Cap. Flow %
11.9%
Top 10 Hldgs %
46.64%
Holding
93
New
15
Increased
28
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.95M
2
GNCA
Genocea Biosciences, Inc.
GNCA
+$2.53M
3
AUTL
Autolus Therapeutics
AUTL
+$2.24M
4
EPZM
Epizyme, Inc
EPZM
+$2.23M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$2.16M

Top Sells

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$1.59M
2
ADXS
Advaxis Inc
ADXS
+$1.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$884K
4
SVRA icon
Savara
SVRA
+$813K
5
MRSN
Mersana Therapeutics
MRSN
+$603K

Sector Composition

Rank Sector Weight
1 Healthcare 95.88%
2 Miscellaneous 4.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$39.7M 14.91%
13,680,554
– –
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$22.7M 8.52%
123,806
– –
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$11.6M 4.37%
123,218
+3,500
+3% +$289K
ATRC icon
4
AtriCure
ATRC
$2.47B
$9.51M 3.58%
318,729
– –
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
$7.49M 2.81%
636,013
+65,000
+11% +$787K
ASND icon
6
Ascendis Pharma A/S
ASND
$16.3B
$6.84M 2.57%
59,380
+15,000
+34% +$1.79M
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$6.77M 2.54%
52,509
+2,900
+6% +$344K
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$6.73M 2.53%
140,764
+11,000
+8% +$443K
IBB icon
9
iShares Biotechnology ETF
IBB
$10.5B
$6.7M 2.52%
61,400
– –
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
$6.07M 2.28%
205,440
+53,670
+35% +$2.07M
WVE icon
11
Wave Life Sciences
WVE
$993M
$5.68M 2.13%
217,554
+27,000
+14% +$757K
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.51M 2.07%
93,942
– –
ARQL
13
DELISTED
Arqule Inc
ARQL
$5.48M 2.06%
497,762
+124,598
+33% +$867K
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.7B
$5.46M 2.05%
64,608
+9,600
+17% +$788K
DXCM icon
15
DexCom
DXCM
$34.3B
$5.45M 2.05%
145,352
+16,000
+12% +$503K
CYTK icon
16
Cytokinetics
CYTK
$10B
$5.37M 2.02%
477,196
+76,902
+19% +$742K
ARGX icon
17
argenx
ARGX
$64B
$4.5M 1.69%
31,750
-3,900
-11% -$495K
TVRD
18
Tvardi Therapeutics
TVRD
$24.3M
$4.41M 1.66%
5,695
+1,706
+43% +$1.2M
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.16M 1.56%
95,000
+15,000
+19% +$846K
AKBA icon
20
Akebia Therapeutics
AKBA
$243M
$4.02M 1.51%
830,538
+115,000
+16% +$654K
LMNX
21
DELISTED
Luminex Corp
LMNX
$4.01M 1.51%
194,091
+55,700
+40% +$1.22M
ELOX
22
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$3.74M 1.41%
+9,375
New +$3.95M
YARW
23
Yarrow Bioscience
YARW
$98.8M
$3.59M 1.35%
167
– –
XENE icon
24
Xenon Pharmaceuticals
XENE
$5.81B
$3.26M 1.23%
330,667
– –
BLUE
25
DELISTED
bluebird bio
BLUE
$3.24M 1.22%
1,969
-115
-6% -$199K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, DAFNA Capital Management held 93 positions worth $266M, up 15% from $232M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $31.7M of net new capital in Q2 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $603K trimmed.

  • DAFNA Capital Management's largest Q2 2019 buy was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.
  • DAFNA Capital Management added most to Genocea Biosciences, Inc. in Q2 2019, an estimated $2.53M increase.
  • DAFNA Capital Management's biggest Q2 2019 reduction was Mersana Therapeutics, cutting an estimated $603K.
  • DAFNA Capital Management fully exited VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019, selling an estimated $1.59M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $266M portfolio in Q2 2019.
  • DAFNA Capital Management opened 15 new positions and closed 6 in Q2 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.